Radium Ra 223 Dichloride

CHEMBL2107816 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A targeted radioactive therapy used to treat prostate cancer that has spread to the bones, working by emitting radiation directly to bone metastases while minimizing exposure to surrounding healthy tissue. It can help relieve bone pain and may extend survival in men with castration-resistant prostate cancer.

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl[223Ra]Cl

InChI

InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A targeted radioactive therapy used to treat prostate cancer that has spread to the bones, working by emitting radiation directly to bone metastases while minimizing exposure to surrounding healthy tissue. It can help relieve bone pain and may extend survival in men with castration-resistant prostate cancer.

Yes, Radium Ra 223 Dichloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107816. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.